| Report ID |
79293 |
| Drug Identification Number |
02091887 |
| Brand name |
RIFADIN |
| Common or Proper name |
Rifadin 150mg |
| Company Name |
SANOFI-AVENTIS CANADA INC |
| Market Status |
CANCELLED POST MARKET |
| Active Ingredient(s) |
RIFAMPIN |
| Strength(s) |
150MG |
| Dosage form(s) |
CAPSULE |
| Route of administration |
ORAL |
| Packaging size |
100 |
| ATC code |
J04AB |
| ATC description |
DRUGS FOR TREATMENT OF TUBERCULOSIS |
| Reason for shortage |
Other (Please describe in comments) |
| Anticipated start date |
2019-06-28 |
| Actual start date |
2019-07-03 |
| Estimated end date |
Unknown |
| Actual end date |
2021-01-28 |
| Shortage status |
Resolved |
| Updated date |
2021-02-16 |
| Company comments |
July 15th, 2020: Rifadin strengths are in Dormant status
The shortage is due to a production delay and an increase in demand. Sanofi is working diligently to make the product available as soon as possible. We are in communication with Health Canada to work towards reducing the duration of the backorder. Sanofi has no supply remaining at its warehouse or at the wholesale level. |
| Health Canada comments |
|
| Tier 3 Status |
No |
| Company contact information |
email: CAINTERNET@sanofi.com
Telephone: 1-800-265-7927 |
